A Potential Long-Acting LDL-Cholesterol–Lowering PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies

The aim of the studies was to evaluate the safety, tolerability, and efficacy of tafolecimab, a novel proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody, in Chinese healthy volunteers and patients with hypercholesterolemia. Fifty-eight healthy volunteers (phase 1a) were random...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yimin, Zhao, Xia, Qi, Litong, Li, Xin, Huang, Zhijun, Yang, Guoping, Qian, Lei, Deng, Huan, Li, Haoyu, Huo, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Cutting Edge Technology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627834/
https://www.ncbi.nlm.nih.gov/pubmed/36341216
http://dx.doi.org/10.1016/j.jacasi.2021.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627834/
https://www.ncbi.nlm.nih.gov/pubmed/36341216
http://dx.doi.org/10.1016/j.jacasi.2021.09.002

Ejemplares similares